Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 871-878

  Britt, Nicholas S ^a,b,c   Potter, Emily M ^c   Patel, Nimish ^d   Steed, Molly E ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

bloodstream infection; daptomycin; Enterococcus; linezolid; vancomycin resistant Enterococcus

Indexed keywords

CREATINE KINASE; DAPTOMYCIN; LINEZOLID; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; COHORT ANALYSIS; COMPARATIVE STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTEROCOCCAL INFECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT ENTEROCOCCUS BLOODSTREAM INFECTION; VETERAN; BACTEREMIA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; DAPTOMYCIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LINEZOLID; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; VANCOMYCIN-RESISTANT ENTEROCOCCI; VETERANS;

EID: 84940655264     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ444     Document Type: Article

References (30)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H,Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
2. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycinresistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007; 58:163-70.
3. Reik R, Tenover FC, Klein E, McDonald LC. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis 2008; 62:81-5.
4. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009; 30:184-6.
5. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003; 24:690-8.
6. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005; 191:588-95.
7. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycinsusceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41:327-33.
8. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
9. Arias CA, Contreras GA, Murray BE. Management of multidrugresistant enterococcal infections. Clin Microbiol Infect 2010; 16:555-62.
10. Zyvox (linezolid for injection) [package insert]. New York: Pharmacia & Upjohn Company, Division of Pfizer, Inc, 2010.
11. Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006; 42:657-68.
12. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009; 29:792-9.
13. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54:567-71.
14. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and-resistant strains. Antimicrob Agents Chemother 2000; 44:1062-6.
15. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of standard-and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012; 56:3174-80.
16. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 2011; 31:527-36.
17. King EA, McCoy D, Desai S, Nyirenda T, Bicking K. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother 2011; 66:2112-8.
18. Wu G, Abraham T, Rapp J, Vastey F, Saad N, Balmir E. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents 2011; 38:192-6.
19. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010; 65:1126-36.
20. Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 2009; 64:175-80.
21. Crank CW, Scheetz MH, Brielmaier B, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther 2010; 32:1713-9.
22. Twilla JD, Finch CK, Usery JB, Gelfand MS, Hudson JQ, Broyles JE. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. J Hosp Med 2012; 7:243-8.
23. McKinnell JA, Patel M, Shirley RM, Kunz DF, Moser SA, Baddley JW. Observational study of the epidemiology and outcomes of vancomycinresistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect 2011; 139:1342-50.
24. Balli EP, Venetis CA, Miyakis S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother 2014; 58:734-9.
25. Whang DW, Miller LG, Partain NM, McKinnell JA. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother 2013; 57:5013-8.
26. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568-74.
27. Steenbergen JN, Mohr JF, Thorne GM. Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 2009; 64:1130-8.
28. Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals Inc, 2012.
29. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 52:228-34.
30. Hayakawa K, Marchaim D, Pogue JM, et al. Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-casecontrol study. Am J Infect Control 2012; 40:e261-3.